1164 related articles for article (PubMed ID: 17121522)
1. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
Sharma PK; Bhansali A; Sialy R; Malhotra S; Pandhi P
Clin Endocrinol (Oxf); 2006 Dec; 65(6):722-8. PubMed ID: 17121522
[TBL] [Abstract][Full Text] [Related]
2. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
3. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
[TBL] [Abstract][Full Text] [Related]
4. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
Miyazaki Y; DeFronzo RA
Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
[TBL] [Abstract][Full Text] [Related]
5. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
[TBL] [Abstract][Full Text] [Related]
6. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.
Kadoglou NP; Kapelouzou A; Tsanikidis H; Vitta I; Liapis CD; Sailer N
Exp Clin Endocrinol Diabetes; 2011 Feb; 119(2):63-8. PubMed ID: 21031343
[TBL] [Abstract][Full Text] [Related]
7. Rosiglitazone improves insulin sensitivity in nonobese subjects with impaired glucose tolerance: the role of adiponectin and C-reactive protein.
Hung YJ; Lin SH; Pei D; Kuo SW; Hsieh CH; He CT; Hsing Lee C; Fan SC; Sheu WH
Metabolism; 2006 Apr; 55(4):439-44. PubMed ID: 16546473
[TBL] [Abstract][Full Text] [Related]
8. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus.
Kadoglou NP; Tsanikidis H; Kapelouzou A; Vrabas I; Vitta I; Karayannacos PE; Liapis CD; Sailer N
Metabolism; 2010 Mar; 59(3):373-9. PubMed ID: 19815243
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes.
Eguchi K; Tomizawa H; Ishikawa J; Hoshide S; Numao T; Fukuda T; Shimada K; Kario K
Hypertens Res; 2007 Jan; 30(1):23-30. PubMed ID: 17460368
[TBL] [Abstract][Full Text] [Related]
10. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome.
Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Piccinni MN; Fogari E; Salvadeo S; Ciccarelli L; Fogari R
Diabetes Res Clin Pract; 2005 Jul; 69(1):5-13. PubMed ID: 15955382
[TBL] [Abstract][Full Text] [Related]
11. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
12. Treatment with a thiazolidinedione increases eye protrusion in a subgroup of patients with type 2 diabetes.
Dorkhan M; Lantz M; Frid A; Groop L; Hallengren B
Clin Endocrinol (Oxf); 2006 Jul; 65(1):35-9. PubMed ID: 16817816
[TBL] [Abstract][Full Text] [Related]
13. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus.
Teranishi T; Ohara T; Maeda K; Zenibayashi M; Kouyama K; Hirota Y; Kawamitsu H; Fujii M; Sugimura K; Kasuga M
Metabolism; 2007 Oct; 56(10):1418-24. PubMed ID: 17884455
[TBL] [Abstract][Full Text] [Related]
14. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study.
Wallace TM; Levy JC; Matthews DR
Diabet Med; 2004 Jun; 21(6):568-76. PubMed ID: 15154941
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM.
Perez A; Zhao Z; Jacks R; Spanheimer R
Curr Med Res Opin; 2009 Dec; 25(12):2915-23. PubMed ID: 19827910
[TBL] [Abstract][Full Text] [Related]
16. Effect of metformin therapy on plasma adiponectin and leptin levels in obese and insulin resistant postmenopausal females with type 2 diabetes.
Adamia N; Virsaladze D; Charkviani N; Skhirtladze M; Khutsishvili M
Georgian Med News; 2007 Apr; (145):52-5. PubMed ID: 17525501
[TBL] [Abstract][Full Text] [Related]
17. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
Derosa G; Maffioli P; Ferrari I; Mereu R; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Salvadeo SA
Horm Metab Res; 2010 Aug; 42(9):663-9. PubMed ID: 20560108
[TBL] [Abstract][Full Text] [Related]
18. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA
Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
[TBL] [Abstract][Full Text] [Related]
19. Correlation between the adiponectin-leptin ratio and parameters of insulin resistance in patients with type 2 diabetes.
Inoue M; Maehata E; Yano M; Taniyama M; Suzuki S
Metabolism; 2005 Mar; 54(3):281-6. PubMed ID: 15736103
[TBL] [Abstract][Full Text] [Related]
20. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin.
Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
Intern Med J; 2007 Feb; 37(2):79-86. PubMed ID: 17229249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]